Ribozyme mediated inactivation of the androgen receptor
AssigneeBoard of Regents, The University of Texas System
InventorsArun K Roy, Shuo Chen
Life of this patent
Estimating the term…
Abstract
The present invention provides synthetic ribozyme oligonucleotides alone and within constructs. The ribozyme gene provides methods for the treatment of prostate hyperplasia and other androgen dependent pathologies. Improved therapies for such diseases are provided without significant hormonal imbalance and without surgical intervention. Also provided are techniques for selecting and synthesizing effective and specifically targeted molecular tools for use in inhibiting androgen receptor gene expression.
Claims32
A synthetic ribozyme that cleaves androgen receptor mRNA, comprising first and second ribozyme side arms flanking a catalytic domain, wherein said first and second ribozyme side arms comprise sequences complementary to the target human androgen receptor mRNA sequence of SEQ ID NO:1.
A synthetic ribozyme that cleaves the target human androgen receptor mRNA, comprising a central catalytic core with a conserved stem loop structure, a first specifier sequence on the 5′ side of the catalytic core and a second specifier sequence on the 3′ side of the catalytic core, wherein said first and second specifier sequences are complementary to the target human androgen receptor mRNA sequence of SEQ ID NO:1.
A synthetic ribozyme that cleaves androgen receptor mRNA;
- wherein said ribozyme comprises the sequence of SEQ ID NO:11 or SEQ ID NO:13.
Dependencies are inferred from the claim text.